[go: up one dir, main page]

AR075071A1 - COMPUESTOS DERIVADOS DE SULFONAMIDAS , USO DE LOS MISMOS PARA LA PREPARACIoN DE MEDICAMENTOS , COMPOSICIONES FARMACÉUTICAS Y PROCESO DE PREPARACIoN DE LOS MISMOS - Google Patents

COMPUESTOS DERIVADOS DE SULFONAMIDAS , USO DE LOS MISMOS PARA LA PREPARACIoN DE MEDICAMENTOS , COMPOSICIONES FARMACÉUTICAS Y PROCESO DE PREPARACIoN DE LOS MISMOS

Info

Publication number
AR075071A1
AR075071A1 ARP090102946A ARP090102946A AR075071A1 AR 075071 A1 AR075071 A1 AR 075071A1 AR P090102946 A ARP090102946 A AR P090102946A AR P090102946 A ARP090102946 A AR P090102946A AR 075071 A1 AR075071 A1 AR 075071A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
optionally substituted
groups
alkyl
atoms
Prior art date
Application number
ARP090102946A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR075071A1 publication Critical patent/AR075071A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/52—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula 1: o solvatos, hidratos o sales farmacéuticamente aceptables del mismo, en donde: R1 es H, un grupo carbocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, un grupo heterocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, (alquilo de 1 a 4 átomos de carbono)-grupo carbocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, (alquilo de 1 a 4 átomos de carbono)-grupo heterocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, alquilo de 1 a 6 átomos de carbono opcionalmente sustituido por uno o más átomos de halogeno, grupos CN u OH, alcoxilo de 1 a 6 átomos de carbono opcionalmente sustituido por uno o más átomos de halogeno o grupos OH, o un grupo éter que contiene de 2 a 10 átomos de carbono y de 1 a 3 átomos de oxígeno, en donde el grupo éter está opcionalmente sustituido por uno o más sustituyentes, cada uno independientemente seleccionado a partir de OH, halogeno, un grupo carbocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, y un grupo heterocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z; R2 es un grupo carbocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, un grupo heterocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, (alquilo de 1 a 4 átomos de carbono)-grupo carbocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, (alquilo de 1 a 4 átomos de carbono)-grupo heterocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, alquilo de 1 a 6 átomos de carbono opcionalmente sustituido por uno o más átomos de halogeno, grupos CN u OH, alcoxilo de 1 a 6 átomos de carbono opcionalmente sustituido por uno o más átomos de halogeno o grupos OH, o un grupo éter que contiene de 2 a 10 átomos de carbono y de 1 a 3 átomos de oxígeno, en donde el grupo éter está opcionalmente sustituido por uno o más sustituyentes, cada uno independientemente seleccionado a partir de OH, halogeno, un grupo carbocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, y un grupo heterocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z; o R1 y R2 junto con el átomo de carbono con el que están unidos, forman un grupo carbocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, o un grupo heterocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z; R3 es hidrogeno, halogeno o ciano; R4 es H, alquilo de 1 a 8 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono, cicloalquenilo de 5 a 8 átomos de carbono o (alquilo de 1 a 4 átomos de carbono)-R6, en donde los grupos alquilo están cada uno opcionalmente sustituidos por uno o más átomos de halogeno; R5 es alquilo de 1 a 8 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono, cicloalquenilo de 5 a 8 átomos de carbono, (alquilo de 1 a 4 átomos de carbono) cicloalquilo de 3 a 8 átomos de carbono o (alquilo de 1 a 4 átomos de carbono)-cicloalquenilo de 5 a 8 átomos de carbono, en donde los grupos alquilo están cada uno opcionalmente sustituidos por uno o más átomos de halogeno: o R4 y R5, junto con los átomos de nitrogeno y oxígeno con los que están unidos, forman un grupo heterocíclico de 5 a 10 miembros opcionalmente sustituido por uno o más grupos Z; R6 se selecciona a partir de un grupo carbocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, un grupo heterocíclico de 3 a 10 miembros opcionalmente sustituido por uno o más grupos Z, NR7R9, NR7(SO2)R9, (SO2)NR7R8, (SO2)R9, NR7C(O)R9, C(O)NR7R9, NR7C(O)NR8R9, NR7C(O)OR9, C(O)OR7, OC(O)R9, OC(O)NR7, C(O)R9, SR7, CN y NO2; R7 y R8 se seleccionan cada uno independientemente a partir de H, alquilo de 1 a 6 átomos de carbono, cicloalquilo de 3 a 10 átomos de carbono, cicloalquenilo de 5 a 10 átomos de carbono y -(alquileno de 1 a 3 átomos de carbono)-cicloalquilo de 3 a 10 átomos de carbono; R9 se selecciona a partir de H, alquilo de 1 a 6 átomos de carbono, -(alquileno de 1 a 3 átomos de carbono)-cicloalquilo de 3 a 10 átomos de carbono, un grupo carbocíclico de 3 a 10 miembros, y un grupo heterocíclico de 3 a 10 miembros, en donde cada uno de los grupos alquilo y sistemas de anillos está opcionalmente sustituido por OH, halogeno, alquilo de 1 a 3 átomos de carbono, y alcoxilo de 1 a 3 átomos de carbono; X es CR14 o N; Z se selecciona independientemente a partir de OH; un grupo carbocíclico de 3 a 10 miembros: un grupo heterocíclico de 3 a 10 miembros; bencilo; alquilo de 1 a 6 átomos de carbono opcionalmente sustituido por uno o más átomos de halogeno, grupos CN u OH; alcoxilo de 1 a 6 átomos de carbono opcionalmente sustituido por uno o más átomos de halogeno, grupos CN u OH; -Oarilo; -Obencilo; -O(CH2)aC(O)E; NR10(SO2)R12 (SO2)NR10R11; (SO2)R12; NR10C(O)R12; C(O)NR10R12; NR10C(O)NR11R12; NR10C(O)OR12; NR10R12; C(O)OR10; OC(O)R12; OC(O)NR10; C(O)R12; SR12; CN; NO2 y halogeno; o en donde hay dos o más sustituyentes Z, dos sustituyentes Z junto con los átomos con los que están unidos opcionalmente forman un sustituyente carbocíclico de 5 a 7 miembros o heterocíclico de 4 a 7 miembros fusionado con el sistema de anillos; a es 0, 1, 2, 3 o 4, en donde el grupo alquileno está opcionalmente sustituido por OH o NH, cuando a es 1, 2, 3 o 4; E es NR10R12 u OR12; cada R10 y R11 se selecciona independientemente a partir de H, alquilo de 1 a 6 átomos de carbono, cicloalquilo de 3 a 10 átomos de carbono, cicloalquenilo de 5 a 10 átomos de carbono y -(alquileno de 1 a 3 átomos de carbono)-cicloalquilo de 3 a 10 átomos de carbono; cada R12 se selecciona a partir de H, alquilo de 1 a 6 átomos de carbono, -(alquileno de 1 a 3 átomos de carbono)-cicloalquilo de 3 a 10 átomos de carbono, un grupo carbocíclico de 3 a 10 miembros, y un grupo heterocíclico de 3 a 10 miembros, en donde cada uno de los sistemas de anillos está opcionalmente sustituido por OH, halogeno, alquilo de 1 a 3 átomos de carbono, y alcoxilo de 1 a 3 átomos de carbono; y R14 es H o alquilo de 1 a 6 átomos de carbono. Reivindicacion 10: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 8, en la fabricacion de un medicamento para el tratamiento de condiciones o enfermedades inflamatorias o alérgicas. Reivindicacion 12: Una composicion farmacéutica, la cual comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 8, junto con un vehiculo o excipiente farmacéuticamente aceptable. Reivindicacion 14: Un proceso para la preparacion de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 8, cuyo proceso comprende hacer reaccionar un compuesto de la formula 2: en donde R3, R4 y R5 son como se definen en la reivindicacion 1, con un compuesto de la formula 3: en donde X, R1 y R2 son como se definen en la reivindicacion 1; aislar el producto.
ARP090102946A 2008-08-04 2009-07-31 COMPUESTOS DERIVADOS DE SULFONAMIDAS , USO DE LOS MISMOS PARA LA PREPARACIoN DE MEDICAMENTOS , COMPOSICIONES FARMACÉUTICAS Y PROCESO DE PREPARACIoN DE LOS MISMOS AR075071A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161765 2008-08-04
US16162709P 2009-03-19 2009-03-19

Publications (1)

Publication Number Publication Date
AR075071A1 true AR075071A1 (es) 2011-03-09

Family

ID=39769571

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102946A AR075071A1 (es) 2008-08-04 2009-07-31 COMPUESTOS DERIVADOS DE SULFONAMIDAS , USO DE LOS MISMOS PARA LA PREPARACIoN DE MEDICAMENTOS , COMPOSICIONES FARMACÉUTICAS Y PROCESO DE PREPARACIoN DE LOS MISMOS

Country Status (34)

Country Link
US (5) US7989497B2 (es)
EP (1) EP2310359B1 (es)
JP (1) JP5303645B2 (es)
KR (1) KR101310503B1 (es)
CN (1) CN102171183B (es)
AR (1) AR075071A1 (es)
AU (1) AU2009279123B2 (es)
BR (1) BRPI0916995B8 (es)
CA (1) CA2732932C (es)
CO (1) CO6341623A2 (es)
CU (2) CU24038B1 (es)
DK (1) DK2310359T3 (es)
EA (1) EA020374B1 (es)
EC (1) ECSP11010804A (es)
ES (1) ES2458596T3 (es)
HN (1) HN2011000341A (es)
HR (1) HRP20140350T1 (es)
IL (1) IL210836A (es)
JO (1) JO2910B1 (es)
MA (1) MA32536B1 (es)
MX (1) MX2011001378A (es)
MY (1) MY155626A (es)
NZ (1) NZ590708A (es)
PE (1) PE20110205A1 (es)
PL (1) PL2310359T3 (es)
PT (1) PT2310359E (es)
RS (1) RS53264B (es)
SI (1) SI2310359T1 (es)
SV (1) SV2011003831A (es)
TW (1) TWI430791B (es)
UA (1) UA103198C2 (es)
UY (1) UY32025A (es)
WO (1) WO2010015613A1 (es)
ZA (1) ZA201100512B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
AU2016201916A1 (en) * 2011-09-02 2016-04-21 Novartis Ag Choline salt of an anti-inflammatory substituted cyclobutenedione compound
PL2760821T3 (pl) * 2011-09-02 2018-04-30 Novartis Ag Sól cholinowa przeciwzapalnego związku podstawionego cyklobutenodionem
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr) * 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
HK1223978A1 (zh) 2013-06-18 2017-08-11 New York University 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
CA3072671A1 (en) * 2017-08-14 2019-02-21 Allergan, Inc. 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
US11207294B2 (en) 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020058869A1 (en) 2018-09-21 2020-03-26 Pfizer Inc. N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
CN112759549B (zh) * 2019-11-05 2023-07-28 中国医学科学院药物研究所 3-取代氨基-4-((取代吡啶基)氨基)环丁-3-烯-1,2-二酮类化合物
CN112851635B (zh) * 2019-11-28 2022-09-16 中国医学科学院药物研究所 环状砜类化合物及其制备方法、用途和药物组合物
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
IL302553A (en) * 2020-11-05 2023-07-01 Icahn School Med Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3216717A1 (en) 2021-04-30 2022-11-03 Mind Medicine, Inc. Lsd salt crystal forms
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
US12527786B2 (en) 2021-08-19 2026-01-20 Mind Medicine, Inc. Immediate release formulations of d-lysergic acid diethylamide for therapeutic applications
WO2025149577A1 (en) * 2024-01-11 2025-07-17 Julius-Maximilians-Universitaet Wuerzburg 18f-cxcr2 pet tracer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354763A (en) * 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
JP2002534498A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤としてのベンゼンスルホンアミド誘導体およびその使用
DE60216229T2 (de) * 2001-01-16 2007-10-04 Smithkline Beecham Corp. Il-8-rezeptorantagonisten
US20040110954A1 (en) 2001-03-30 2004-06-10 Palovich Michael R. Methods of synthesizing phenol-contining compounds
PL208928B1 (pl) 2001-04-16 2011-06-30 Pharmacopeia 3, 4-di-podstawione cyklobuten-1, 2-diony jako ligandy receptora CXC chemokiny
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
MXPA04009127A (es) 2002-03-18 2005-01-25 Schering Corp Tratamiento de enfermedades mediadas por quimiocinas.
JP2007519751A (ja) 2004-01-30 2007-07-19 シェーリング　コーポレイション Ｃｘｃ−ケモカインレセプターリガンドの結晶多形
DE102005001053A1 (de) 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
JP2008530284A (ja) 2005-02-10 2008-08-07 ワッカー ケミー アクチエンゲゼルシャフト 保護されたイソシアネート基を有する粒子を含有する塗料
WO2006088920A1 (en) 2005-02-16 2006-08-24 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
AU2007269572A1 (en) 2006-07-07 2008-01-10 Pharmacopeia, Inc. 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP2139852A1 (en) * 2006-12-19 2010-01-06 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
BRPI0812222A2 (pt) * 2007-06-06 2014-12-16 Novartis Ag Compostos ciclobutenodiona substituídos anti-inflamatórios.
CN101932553A (zh) 2007-07-03 2010-12-29 先灵公司 合成1,2-取代的3,4-二氧代-1-环丁烯化合物的方法和中间体
CN101778836A (zh) 2007-07-05 2010-07-14 先灵公司 在1,2-取代的3,4-二氧-1-环丁烯化合物中控制的晶体大小的方法
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
US20110009482A1 (en) 2007-12-04 2011-01-13 Schering Corporation Methods of treating copd
PT2444120T (pt) 2007-12-10 2018-01-03 Novartis Ag Análogos da amilorida espirocíclicos como bloqueadores de enac
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists
PL2760821T3 (pl) 2011-09-02 2018-04-30 Novartis Ag Sól cholinowa przeciwzapalnego związku podstawionego cyklobutenodionem

Also Published As

Publication number Publication date
CA2732932A1 (en) 2010-02-11
US20130005735A1 (en) 2013-01-03
MX2011001378A (es) 2011-03-25
HK1155151A1 (en) 2012-05-11
ECSP11010804A (es) 2011-03-31
EA201100299A1 (ru) 2011-10-31
CU20110030A7 (es) 2011-12-28
MA32536B1 (fr) 2011-08-01
CU24038B1 (es) 2014-11-27
CO6341623A2 (es) 2011-11-21
TWI430791B (zh) 2014-03-21
JP5303645B2 (ja) 2013-10-02
KR20110038168A (ko) 2011-04-13
US20110251205A1 (en) 2011-10-13
IL210836A0 (en) 2011-04-28
US8288588B2 (en) 2012-10-16
EP2310359B1 (en) 2014-01-15
UA103198C2 (en) 2013-09-25
PT2310359E (pt) 2014-04-23
SI2310359T1 (sl) 2014-05-30
BRPI0916995B1 (pt) 2020-03-10
US20100029670A1 (en) 2010-02-04
TW201010690A (en) 2010-03-16
MY155626A (en) 2015-11-13
CN102171183A (zh) 2011-08-31
PL2310359T3 (pl) 2014-06-30
AU2009279123A1 (en) 2010-02-11
US8329754B2 (en) 2012-12-11
DK2310359T3 (da) 2014-04-07
EP2310359A1 (en) 2011-04-20
BRPI0916995A2 (pt) 2015-11-24
WO2010015613A1 (en) 2010-02-11
SV2011003831A (es) 2011-07-05
US8722925B2 (en) 2014-05-13
JP2011529940A (ja) 2011-12-15
PE20110205A1 (es) 2011-04-07
CA2732932C (en) 2017-04-18
HRP20140350T1 (hr) 2014-05-23
KR101310503B1 (ko) 2013-09-27
US20140213594A1 (en) 2014-07-31
CU20110142A6 (es) 2012-01-31
EA020374B1 (ru) 2014-10-30
ZA201100512B (en) 2011-10-26
US7989497B2 (en) 2011-08-02
HN2011000341A (es) 2013-07-29
US20110251206A1 (en) 2011-10-13
UY32025A (es) 2010-03-26
BRPI0916995B8 (pt) 2021-05-25
RS53264B (sr) 2014-08-29
US9115087B2 (en) 2015-08-25
JO2910B1 (en) 2015-09-15
IL210836A (en) 2014-11-30
AU2009279123B2 (en) 2012-08-23
ES2458596T3 (es) 2014-05-06
NZ590708A (en) 2012-07-27
CN102171183B (zh) 2013-12-25

Similar Documents

Publication Publication Date Title
AR075071A1 (es) COMPUESTOS DERIVADOS DE SULFONAMIDAS , USO DE LOS MISMOS PARA LA PREPARACIoN DE MEDICAMENTOS , COMPOSICIONES FARMACÉUTICAS Y PROCESO DE PREPARACIoN DE LOS MISMOS
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
AR079689A1 (es) Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias.
AR078786A1 (es) Derivados de la cromenona
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR061858A1 (es) Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR080187A1 (es) Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen.
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR066492A1 (es) Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres.
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
AR079231A1 (es) Derivados de imidazoquinolina
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
MX2017002241A (es) Compuestos de aminopirimidina como inhibidores de jak.
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR058010A1 (es) Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto
AR063028A1 (es) Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
AR078164A1 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden
ATE530182T1 (de) Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen
AR062405A1 (es) Derivados de isoindol

Legal Events

Date Code Title Description
FG Grant, registration